Professor Zhiyong Zhang is a professor at Guangzhou Medical University (GMU) and the founding director of the Translational Research Centre of Regenerative Medicine and 3D Printing Technologies at GMU, as well as the Biomedical Engineering Research Center of Guangdong Province. Additionally, he serves as the Group Leader of the State Key Lab of Respiratory Disease in China. Previously, he was a Professor/Group Leader at Shanghai Jiao Tong University and the National Tissue Engineering Centre of China. He has been granted several talent scheme program awards, including the awardee of the First Prize of National Science and Technology Progress Award of China (Top scientific awards in China) and the National Talent Program of China (China’s Recruitment Program of Global Experts), the "Eastern Scholar" Distinguished Professor, and the “Outstanding Medical Academic Leader”. He has filed more than 30 patents, published over 80 academic papers in international journals such as Advanced Science, Bioactive Materials, Small, Biomaterials, and authored five book chapters, also he has awarded more than 20 Research Grants (30M RMB) and has been invited over 40 Keynote lectures at international conferences.
With a long-standing focus on clinical translational research in stem cells and regenerative medicine, Prof. Zhang has successfully translated several technologies into clinical practice. He dedicated to create the DASEA Bio-manufacturing platform, to achieve the "5" goals for the scalable manufacturing of biological products such as cells and exosomes: Digitalized, Automated, Scalable, Enclosed, Activated. The DASEA Bio-manufacturing platform can overcome the bottleneck issues associated with traditional 2D cell culture tech, reduce production cost significantly, enhance cell quality and stability, expedite clinical translation and industrialization. The stem cells and exosomes prepared by DASEA have obtained quality inspection reports from the NIFDC and been recognized by China NMPA, as well as several large tertiary hospitals to conduct multiple clinical trials. These clinical studies have demonstrated excellent therapeutic outcomes, showcasing the safety and effectiveness of the DASEA Biomanufacturing Platform.
|
Lu Yin is a professor at the First Affiliated Hospital of Nanchang University and a principal investigator at the Jiangxi Provincial Key Laboratory of Respiratory Disease. He also serves as a committee member of the Medical Innovation and Translation Branch of Jiangxi Integrative Medicine Society, and a member of the Youth Working Committee of Jiangxi Biochemistry and Molecular Biology Society. He was a recipient of the Research Fund for International Excellent Young Scientists awarded by the National Natural Science Foundation of China, and was selected for the “Two-Thousand” Talent Program of Jiangxi Province. Before assuming his current roles in China, Lu Yin gained valuable experiences as a research fellow at the Singapore-MIT alliance for Research and Technology, the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR Singapore). His research focuses on developing effective and consistent stem cell therapy solutions through a synergistic integration of microfluidic, machine-learning, and conventional molecular biology technologies. Lu Yin has led 5 national research grants in China and Singapore. He was also a team leader representing the Bioprocessing Technology Institute of A*STAR on 4 collaborative projects with esteemed international industries. He has published over 20 research articles in reputable journals such as Biomaterials, Lab on a Chip, etc., and authored one international academic book chapter. He has been invited to present his research at international conferences hosted by the International Society for Cell & Gene Therapy, Tissue Engineering International & Regenerative Medicine Society, and Biomedical Engineering Society.
|